LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

LLY

974.96

-1.19%↓

JNJ

222.47

-0.89%↓

ABBV

202.58

-1.21%↓

UNH

369.71

+0.7%↑

AZN

182.23

-1.36%↓

Inicio・Lista de Acciones・Treace Medical Concepts Inc

Treace Medical Concepts Inc

Cerrado

1.92 -1.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.8599999999999999

Máximo

1.98

Métricas clave
By Trading Economics
Ingresos	6.9M -9.4M
Ventas	12M 63M
Margen de beneficios	-15.026
Empleados	450
EBITDA	7M -5.2M

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	+111.4% upside

Dividendos
By Dow Jones
Próximas Ganancias	8 may 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-9.5M 119M
Apertura anterior	3.46
Cierre anterior	1.92

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

7.16 / 7.65 Soporte y Resistencia

Treace Medical Concepts Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 may 2026, 23:58 UTC

Ganancias

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7 may 2026, 22:57 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7 may 2026, 23:52 UTC

Ganancias

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7 may 2026, 23:45 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7 may 2026, 23:39 UTC

Charlas de Mercado

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7 may 2026, 23:28 UTC

Charlas de Mercado

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7 may 2026, 23:11 UTC

Ganancias

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7 may 2026, 23:06 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7 may 2026, 23:05 UTC

Ganancias

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7 may 2026, 23:04 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7 may 2026, 23:03 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7 may 2026, 23:02 UTC

Ganancias

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7 may 2026, 23:00 UTC

Charlas de Mercado

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 may 2026, 22:45 UTC

Charlas de Mercado

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7 may 2026, 22:42 UTC

Ganancias

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7 may 2026, 22:33 UTC

Ganancias

Adquisiciones, fusiones, absorciones

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7 may 2026, 22:32 UTC

Ganancias

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7 may 2026, 22:31 UTC

Ganancias

Macquarie: 68% of FY Income From International >MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7 may 2026, 22:30 UTC

Ganancias

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7 may 2026, 22:29 UTC

Ganancias

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7 may 2026, 22:28 UTC

Ganancias

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7 may 2026, 22:27 UTC

Ganancias

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7 may 2026, 22:26 UTC

Ganancias

Macquarie to End Share Buyback Extended in November>MQG.AU

7 may 2026, 22:25 UTC

Ganancias

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Comparación entre iguales

Cambio de precio

Treace Medical Concepts Inc previsión

Precio Objetivo

By TipRanks

111.4% repunte

Estimación a 12 Meses

Media 4.08 USD 111.4%

Máximo 7 USD

Mínimo 2.25 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Treace Medical Concepts Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

4 ratings

Comprar

Mantener

Vender

De acuerdo con 4 analistas que ofrecen calificaciones bursátiles a para Treace Medical Concepts Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

7.16 / 7.65Soporte y Resistencia

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There is one bullish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Treace Medical Concepts Inc

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.